

## A year of unstinted growth

04 July 2015 | Analysis | By BioSpectrum Bureau

### A year of unstinted growth



#### Singapore:

**Aurobindo Pharma, India**

**Chairman:** Mr N Govindarajan

**Revenue:** \$1765.5 mn

**Business:** Manufacturer of APIs

A well-integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70 percent of its revenues derived out of international operations. Aurobindo Pharma is among the largest filers of Drug Master Files and ANDAs from

India.

Last fiscal year will be remembered by the company for both its drug approvals as well as legal issues. Aurobindo announced the completion of acquisition of the US-based Natrol, a move that helps the drugmaker strengthen its OTC profile. The acquisition will help Aurobindo to build an integrated OTC profile and also provide the company an entry into potential high growth markets.

The company announced that it has received final approvals from the US Food and Drug Administration (USFDA) to manufacture and market Cefixime for Oral Suspension USP, 100mg/5mL and 200mg/5mL (ANDA 204835). According to IMS Health, the product had an estimated market size of \$123 million for the twelve months ending February 2015.

Increasing its investments on capital expenditure (capex), Aurobindo said that it planned to spend nearly Rs 1300 crores towards capex during the ongoing and next financial years. The company indicated that the majority of the expenditure will be invested in expanding its active pharmaceutical ingredient unit in Vizag, as well as expanding its injectable portfolio at its Hyderabad site.